Fexofenadine: Biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 7, 2009, Pages 813-822

  Smith, Steven M ^a   Gums, John G ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Allergic rhinitis; Antihistamine; Fexofenadine; H1 antihistamine; Nonsedating

Indexed keywords

ANTIHISTAMINIC AGENT; AZITHROMYCIN; CETIRIZINE; CHLORPHENIRAMINE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; DESLORATADINE; DIPHENHYDRAMINE; EOTAXIN; ERYTHROMYCIN; FEXOFENADINE; GENERIC DRUG; GLYCOPROTEIN P; HYPERICUM PERFORATUM EXTRACT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; ITRACONAZOLE; KETOCONAZOLE; KETOTIFEN; LEVOCETIRIZINE; LORATADINE; MULTIDRUG RESISTANCE PROTEIN 1; PLACEBO; PROMETHAZINE; QUERCETIN; RANTES; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNINDEXED DRUG; VERAPAMIL;

ALLERGIC DISEASE; ALLERGIC RHINITIS; ANTICHOLINERGIC EFFECT; ANTIINFLAMMATORY ACTIVITY; APPLE JUICE; AREA UNDER THE CURVE; CHRONIC URTICARIA; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HAY FEVER; HUMAN; HYPERICUM PERFORATUM; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; ORANGE JUICE; REVIEW; SEDATION; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING;

ANIMALS; ANTI-ALLERGIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERSENSITIVITY; TERFENADINE;

EID: 67650726930     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903044967     Document Type: Review

References (87)

1. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008;122:S1-84 (Pubitemid 352033573)
2. McCrory DC, Williams JW, Dolor RJ, et al. Management of allergic rhinitis in the working-age population. Evidence Report/ Technology Assessment Number 67. Rockville, MD; 2003
3. House of Lords Select Committee on Science and Technology. Allergy. Sixth report, session 2006-2007. London: the stationary office; 2007
4. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758-764 (Pubitemid 39504428)
5. Zhang L, Han D, Huang D, et al. Prevalence of self-reported allergic rhinitis in eleven major cities in China. Int Arch Allergy Immunol 2009;149:47-57
6. Long A, McFadden C, DeVine D, et al. Management of allergic and nonallergic rhinitis. Evidence Report/Technology Assessment No. 54. AHRQ Pub No 02-E024. Rockville, MD: agency for healthcare research and quality; 2002
7. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997;77(4):1033-1079
8. Wuthrich B, Brignoli R, Canevascini M, et al. Epidemiological survey in hay fever patients: symptom prevalence and severity and influence on patient management. Schweizer Med Wochenschr 1998;128:139-143 (Pubitemid 28052760)
9. Togias A. Unique mechanistic features of allergic rhinitis. J Allergy Clin Immunol 2000;105:S599-604 (Pubitemid 30399793)
10. White MV, Kaliner MA. Mediators of allergic rhinitis. J Allergy Clin Immunol 1992;90:699-704
11. Hansen I, Klimek L, Mösges R, Hörmann K. Mediators of inflammation in the early and late phase of allergic rhinitis. Curr Opin Allergy Clin Immunol 2004;4(3):159-163 (Pubitemid 38685515)
12. Gelfand EW. Role of histamine in the pathophysiology of asthma: immunomodulatory and anti-inflammatory activities of H1-receptor antagonists. Am J Med 2002;113:S2-7 (Pubitemid 36459491)
13. Taylor-Clark TE. Insights into the mechanisms of histamine-induced inflammation in the nasal mucosa. Pulm Pharmacol Ther 2008;21(3):455-460 (Pubitemid 351625930)
14. Meltzer EO. An overview of current pharmacotherapy in perennial. rhinitis 1995;95:1097-1110
15. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the joint task force on practice parameters in allergy, asthma, and immunology. American academy of allergy, asthma and immunology. Ann Allergy Asthma Immunol 1998;81(5):478-518 (Pubitemid 28553778)
16. International Rhinitis Management Working Group. International consensus report on the diagnosis and management of rhinitis. Allergy 1994;49:S1-34
17. van Cauwenberge P, Bachert C, Passalacqua G, et al. European academy of allergology and clinical immunology: consensus statement on the treatment of allergic rhinitis. Allergy 2000;55:116-134
18. Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol 2000;105(6):S622-7
19. Leurs R, Church MK, Taglialatela M. H1 antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002;32:489-498 (Pubitemid 34429565)
20. DaBuske L, Kowal K. Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep 2009;9:140-148
21. Allegra [prescribing information]. Bridgewater (NJ): sanofi-aventis US, LLC, 2008
22. Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine, and levocetirizine: a comparative review. Clin Pharmacokinet 2008;47(4):217-230
23. Ciprandi G, Tosca MA, Cosentino C, et al. Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules. J Allergy Clin Immunol 2003;112:S78-82 (Pubitemid 37243980)
24. Chen C. Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans. Drugs R D 2007;8(5):301-314 (Pubitemid 47403125)
25. Triggiani M, Gentile M, Secondo A, et al. Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. J Immunol 2001;166:4083-4091 (Pubitemid 32224939)
26. Asano K, Kanai K, Suzaki H. Suppressive activity of fexofenadine hydrochloride on the production of eosinophil chemoattractants from human nasal fibroblasts in vitro. Arzneimittelforschung 2004;54:436-443 (Pubitemid 39119240)
27. Asano K, Kanai K, Suzaki H. Suppressive activity of fexofenadine hydrochloride on thymus- and activation-regulated chemokine production from human peripheral blood leukocytes in response to antigenic stimulation in vitro. Int Arch Allergy Immunol 2004;133:267-275 (Pubitemid 38529220)
28. Sandoval-López G, Teran LM. TARC: novel mediator of allergic inflammation. Clin Exp Allergy 2001;31:1809-1812 (Pubitemid 34014725)
29. Juergens UR, Gillissen A, Uen S, et al. New evidence of H1-receptor independent COX-2 inhibition by fexofenadine HCl in vitro. Pharmacology 2006;78:129-135 (Pubitemid 44764028)
30. Asano K, Kanai K, Furuta A, et al. Suppressive activity of fexofenadine hydrochloride on nitric oxide production in-vitro and in-vivo. J Pharm Pharmacol 2007;59:1389-1395 (Pubitemid 47606454)
31. Tateishi T, Miura M, Suzuki T, Uno T. The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol 2008;65(5):693-700
32. Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol 2004;18:399-411 (Pubitemid 39215352)
33. Kim KA, Park PW, Park JY. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. Eur J Clin Pharmacol 2009; doi 10.1007/s00228-009-0627-6
34. Wang Z, Hamman MA, Huang SM, et al. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002;71:414-420 (Pubitemid 34701348)
35. Hamman MA, Bruce MA, Haehner-Daniels BD, et al. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001;69:114-121 (Pubitemid 32225411)
36. Lemma GL, Wang Z, Hamman MA, et al. The effect of short- and long-term administration on verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther 2006;79:218-230 (Pubitemid 43297014)
37. Robbins DK, Castles MA, Pack DJ, et al. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 1998;19:455-463 (Pubitemid 28474562)
38. Miura M, Uno T, Tateishi T, Suzuki T. Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality 2007;19:223-227 (Pubitemid 46311056)
39. Dresser GK, Kim RB, Bailey DG. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther 2005;77:170-177 (Pubitemid 40269132)
40. Kamath AV, Yao M, Zhang Y, Chong S. Effect of fruit juices on the oral bioavailability of fexofenadine in rats. J Pharm Sci 2005;94(2):233-239 (Pubitemid 40293320)
41. Golightly LK, Greos LS. Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs 2005;65:341-384 (Pubitemid 40223367)
42. Tahara H, Kusahara H, Fuse E, et al. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab Dispos 2005;33:963-968 (Pubitemid 41002778)
43. Gelfand EW. Inflammatory mediators in allergic rhinitis. J Allergy Clin Immunol 2004;114(5):S135-8
44. Yanai K, Ryu JH, Watanabe T, et al. Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br J Pharmacol 1995;116:1649-1655
45. Tashiro M, Sakurada Y, Iwabuchi K, et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol 2004;44:890-900 (Pubitemid 38971571)
46. Obradovic T, Dobson GG, Shingaki T, et al. Assessment of the first and second generation antihistamines brain penetration and role of p-glycoprotein. Pharm Res 2007;24(2):318-327 (Pubitemid 46072191)
47. Gillman S, Gillard M, Benedetti MS. The concept of receptor occupancy to predict clinical efficacy: a comparison of second generation H1 antihistamines. Allergy Asthma Proc 2009; doi:10.2500/aap.2009.30.3226
48. Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999;104(5):927-933 (Pubitemid 29532110)
49. Horak F, Stübner A, Zieglmayer R, et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001;125:73-79 (Pubitemid 32511103)
50. Horak F, Zieglmayer PU, Zieglmayer R, et al. Levocetirizine has a longer duration of action on improving nasal symptoms score than fexofenadine after single administration. Br J Clin Pharmacol 2005;60:24-31 (Pubitemid 40942777)
51. Anthes JC, Gilchrest H, Richard C, et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamines H1 receptor. Eur J Pharmacol 2002;449:229-237 (Pubitemid 34886479)
52. Meeves SG, Appajosyula S. Efficacy and safety profile of fexofenadine HCl: A unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol 2003;112:S69-77 (Pubitemid 37243979)
53. van Cawenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120mg, loratadine 10mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000;30:891-899 (Pubitemid 30341293)
54. Hampel FC, Kittner B, van Bavel JH. Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitis. Ann Allergy Asthma Immunol 2007;99:549-554
55. Sorkin EM, Heel RC. Terfenadine: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985;29(1):34-56 (Pubitemid 15192974)
56. Bernstein DI, Schoenwetter WF, Nathan RA, et al. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:443-448 (Pubitemid 27514971)
57. Pratt C, Brown AM, Rampe D, et al. Cardiovascular safety of fexofenadine HCl. Clin Exp Allergy 1999;29(Suppl 3):212-216
58. Liu H, Zheng Q, Farley JM. Antimustcarinic actions of antihistamines on the heart. J Biomed Sci 2006;13:395-401
59. Vacchiano C, Moore J, Rice GM, Crawley G. Fexofenadine effects on cognitive performance in aviators at ground level and simulated altitude. Aviat Space Environ Med 2008;79(8):754-760
60. Clark MJ, Million RP. Allergic rhinitis: market evolution. Nat Rev Drug Discov 2009;8:271-272
61. Gupta S, Banfield C, Kantesaria B, et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin Ther 2001;23:451-466 (Pubitemid 32328750)
62. Kharasch ED, Walker A, Hoffer C, et al. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. J Clin Pharmacol 2005;45:79-88 (Pubitemid 40500866)
63. Banfield C, Gupta S, Marino M, et al. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet 2002;41:311-318 (Pubitemid 34533758)
64. Stoltz M, Arumugham T, Lippert C, et al. Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16455A). Biopharm Drug Dispos 1997;18:645-648 (Pubitemid 27394228)
65. Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther 1998;64:612-621 (Pubitemid 29011381)
66. Robertson SM, Davey RT, Voell J, et al. Effect of Ginkgo biloba extract on lopinavir, midazolam, and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 2008;24:591-599 (Pubitemid 351294409)
67. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71:11-20 (Pubitemid 34124034)
68. Yasui-Furukori N, Uno T, Sugawara K, et al. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther 2005;77:17-23 (Pubitemid 40075385)
69. Shimizu M, Uno T, Sugawara K, et al. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 2006;61:538-544
70. Bradley CM, Nicholson AN. Studies on the central effects of the H1-antagonist, loratadine. Eur J Clin Pharmacol 1987;32:419-421 (Pubitemid 17077191)
71. Bender BG, Berning S, Dudden R, et al. Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis. J Allergy Clin Immunol 2003;111:770-776 (Pubitemid 36470247)
72. Shamsi Z, Hindmarch I. Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol Clin Exp 2000;15:S3-30 (Pubitemid 30848077)
73. Layton D, Wilton L, Boshier A, et al. Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England. Drug Saf 2006;29(10):897-909 (Pubitemid 44511590)
74. Salmun LM, Lorber R. 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis. BMC Fam Prac 2002;3:14 (Pubitemid 38994227)
75. Hampel F, Ratner P, Mansfield L, et al. Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003;91(4):354-361 (Pubitemid 37266339)
76. Orzechowski RF, Currie DS, Valancius CA. Comparative anticholinergic activities of 10 histamine H1 receptor antagonists in two functional models. Eur J Pharmacol 2005;506:257-264 (Pubitemid 41071398)
77. Cardelús I, Antón F, Beleta J, Palacios JM. Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle. Eur J Pharmacol 1999;374:249-254 (Pubitemid 29287140)
78. Liu H, Farley JM. Effects of first and second generation antihistamines on muscarinic induced mucus gland cell ion transport. BMC Pharmacol 2005;5:8 (Pubitemid 41460678)
79. Berger WE, Lumry WR, Meltzer EO, Pearlman DS. Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. Allergy Asthma Proc 2006;27(3):214-223 (Pubitemid 44153867)
80. Prenner BM, Capano D, Harris AG. Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: a double-blind comparison with crossover treatment of nonresponders. Clin Ther 2000;22(6):760-769 (Pubitemid 30452000)
81. Wilson AM, Haggart K, Sims EJ, Lipworth BJ. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 2002;32:1504-1509 (Pubitemid 35278920)
82. Lee DKC, Gardiner M, Haggart K, et al. Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin Exp Allergy 2004;34:650-653 (Pubitemid 38534900)
83. Handa S, Dogra S, Kumar B. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. J Dermatol Treat 2004;15:55-57 (Pubitemid 38252098)
84. Meltzer EO, Scheinmann P, Rosado-Pinto JE, et al. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis-a pooled analysis of three studies. Pediatr Allergy Immunol 2004;15:253-260 (Pubitemid 38937570)
85. Milgrom H, Kittner B, Lanier R, Hampel FC. Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old. Ann Allergy Asthma Immunol 2007;99:358-363 (Pubitemid 47606139)
86. Dresser GK, Bailey DG. The effects of fruit juices on drug disposition: a new model for drug interactions. Eur J Clin Invest 2003;33(Suppl):10-16 (Pubitemid 37421611)
87. Hofmann U, Seiler M, Drescher S, et al. Determination of fexofenadine in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002;766:227-233 (Pubitemid 34142354)